Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2016 | MRD negative complete remissions following anti-CD22 CAR in relapsed/refractory ALL

Terry J. Fry • 3 Dec 2016
ASH 2016
Acute Lymphoblastic Leukemia

Press brief presented by Terry J. Fry, MD of Center for Cancer Research, Bethesda, MD, on MRD negative complete remissions following anti-CD22 CAR in children and young adults with relapsed/refractory ALL. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals